This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial
Cummings, J. L.,
Lyketsos, C. G.,
Peskind, E. R.,
Porsteinsson, A. P.,
Mintzer, J. E.,
Scharre, D. W.,
De La Gandara, J. E.,
Agronin, M.,
Davis, C. S.,
Nguyen, U.,
Shin, P.,
Tariot, P. N.,
Siffert, J.
IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August […]
Memantine in moderately-severe-to-severe Alzheimer’s disease: A postmarketing surveillance study
Clerici, Francesca,
Vanacore, Nicola,
Elia, Antonietta,
Spila-Alegiani, Stefania,
Pomati, Simone,
Da Cas, Roberto,
Raschetti, Roberto,
Mariani, Claudio
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug’s effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimer’s disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association criteria has been conducted to date. Objective: […]
Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double‐blind, controlled trial investigating three dosages of cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]
Mild cognitive impairment disease treated with electroacupuncture: a multi-center randomized controlled trial
Zhao, Ling,
Zhang, Fu-Wen,
Zhang, Hong,
Zhao, Yu,
Zhou, Bo,
Chen, Wei-Yin,
Zhu, Man-Jia
Objective: To verify the clinical efficacy on mild cognitive impairment (MCI) treated with electroacupuncture (EA) intervention based on the principle as “promoting the circulation of the Governor Vessel and regulating the marrow” and plan to provide the A-grade evidence of the evidence-based medicine for the clinical treatment of this disease with acupuncture and moxibustion.; Methods: […]
Treatment with Huperzine A improves cognition in vascular dementia patients
Xu, Zhi-Qiang,
Liang, Xiao-Min,
Juan, Wu,
Zhang, Yuan-Feng,
Zhu, Chun-Xia,
Jiang, Xiao-Jiang
Unlabelled: In the present study, we tested the efficacy and safety of Huperzine A in treatment of mild to moderate vascular dementia (VaD). This was a randomized, double-blinded, placebo-controlled study with 78 patients with mild to moderate VaD. The participants were randomized to receive either vitamin C (100-mg bid) as placebo (n = 39) or […]
Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial
Wei, Ming-qing,
Tian, Jin-zhou,
Shi, Jing,
Ma, Fu-yun,
Miao, Ying-chun,
Wang, Yong-yan
Background: Vascular dementia (VaD) is the second common subtype of dementia after Alzheimer’s disease. However, there is still a lack of medication that demonstrates clinically relevant symptomatic improvement. Static blood obstructing the brain is the main Chinese medicine syndrome of VaD.; Objective: To evaluate the effects of Chinese medicine for promoting blood circulation and removing […]
Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer’s disease
Li, Wei,
Zhang, Jie-Wen,
Lu, Fen,
Ma, Ming-Ming,
Wang, Jiang-qiao,
Suo, Ai-Qin,
Bai, Ying-ying,
Liu, Hui-qin
Objective: To explore the effects of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor γ-stimulating activity, on the levels of Aβ1-42, interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and cognition in elderly hypertensive patients with Alzheimer’s disease (AD).; Methods: A total of 48 patients with probable AD and essential hypertension were randomly […]